Study Reveals Why Ozempic Fails for 25% of Users

A major genome-wide study published in Nature has shed new light on why GLP-1 receptor agonist drugs like Ozempic and tirzepatide work dramatically well for some patients while producing little to no weight loss for others. The research, which analyzed data from 27,885 people taking GLP-1 medications, found that approximately 25 percent of users do not respond meaningfully to the drugs.

Genetic Variants and Response

Researchers identified a variant in the GLP1R gene that is linked to significantly greater weight loss — up to 3.3 additional pounds compared to non-carriers. The finding suggests that genetic makeup plays a substantial role in determining how effectively these medications work for individual patients, challenging the assumption that the drugs are universally effective.

Side Effect Prediction

Perhaps most striking was the discovery that two specific genetic variants — rs1800437 and rs10305420 — make patients 15 times more likely to experience severe vomiting when taking tirzepatide. This could explain why some patients abandon treatment due to intolerable side effects while others experience minimal discomfort.

Toward Precision Medicine

On average, study participants lost 25 pounds over eight months on GLP-1 drugs, but individual results varied enormously. The researchers suggest their findings could pave the way for precision medicine approaches, where genetic testing before prescribing would help doctors predict which patients will benefit most and which may need alternative treatments. Such an approach could save patients months of ineffective treatment and reduce unnecessary healthcare costs.